is there still a semaglutide shortage US judge upholds FDA's removal of Ozempic, Wegovy from drug list Ofa Fda Compounded Semaglutide Lawsuit

Orforglipron, Lillys first small-molecule oral GLP-1 receptor agonist in Phase 3, showed meaningful weight loss and glycemic control in adults with type 2 diabetes and overweight or obesity

Experts explain why.

Some patients are reporting breakoutsbut clinical research tells a different story

In clinics across the UK, patients are asking whether they must switch to Wegovy (semaglutide), whether their progress will unravel and whether their future health is now

Semaglutide is a GLP-1 receptor agonist and one of the most extensively researched compounds in the weight loss and metabolic space

Wegovy is an FDA-approved medication for chronic weight management in adults with obesity and overweight with at least one weight-related health condition